Carregant...
Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer
Although oncogenic KRAS represents a therapeutically relevant target in pancreatic cancer, it is deemed “non-druggable” because of the intrinsic difficulty in designing direct inhibitors of KRAS. Our recent work demonstrated a KRAS-integrin-linked kinase (ILK) regulatory feedback loop that allows pa...
Guardat en:
| Publicat a: | Small GTPases |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6204986/ https://ncbi.nlm.nih.gov/pubmed/27936345 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21541248.2016.1251383 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|